ORYX Successfully Completes Phase I/IIa Trial to Treat HPV-Associated Cancers
ORYX announced the successful completion of a Phase I/IIa trial of the therapeutic vaccine VicOryx to treat p16INK4a-overexpressing HPV- (Human Papilloma Virus-) positive cancer patients in an open label, single center trial that included 26 patients. Inclusion criteria for the trial were a history of advanced HPV-positive cervical, vulvar, vaginal, penile, anal or head and neck cancers with diffuse expression of p16INK4a in the tumor, after standard therapy. After an initial interim safety assessment (10 patients), the primary endpoint was the induction of a cellular and/or humoral immune response against the therapeutic vaccine. Secondary endpoints were safety of immunization with VicOryx and tumor response according to RECIST. The vaccine was safe and induced humoral and cellular immune responses. Full data from the trial will be presented at upcoming scientific conferences.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

Taking antibiotics back in time - “Recreating such an ancient molecule was exhilarating, akin to bringing dinosaurs or wooly mammoths back to life”
Pharming and Swedish Orphan announce publication of randomized clinical trial results with recombinant human C1 inhibitor
Nano shake-up - UD researchers demonstrate that processing can affect size of nanocarriers for targeted drug delivery

Biodiesel From Cellulosic Sugars - Agreement between ExxonMobil and Renewable Energy Group
Anti-transglutaminase_antibodies
Yersinia_pestis
Evotec Signs Ion Channel Hit Identification Agreement with Almirall
List_of_subjects_in_Gray's_Anatomy:_XI._Splanchnology
Researchers rapidly turn bacteria into biotech factories
Greater_pancreatic_artery

Lifespin secures bridge financing - Artificial intelligence to determine health status and diagnose diseases
